What does highly emetogenic mean?

(eh-MEH-toh-JEH-nik) Describes a substance that causes vomiting.

Is cyclophosphamide highly emetogenic?

Combined anthracycline and cyclophosphamide regimens have been recently reclassified as highly emetogenic chemotherapy regimen.

What is the emetogenic potential of bevacizumab?

Hint: You can sort the table by clicking on the boxes containing arrows at the top of each column.

Drug NCCN emetogenic potential (2021) ASCO emetogenic potential (2020)
Bevacizumab (Avastin) Minimal Minimal
Bexarotene (Targretin) (oral) Low/Minimal
Bleomycin (Blenoxane) Minimal Minimal
Blinatumomab (Blincyto) Low

How long does the nausea last after chemo?

Acute nausea and vomiting happens within a few minutes to a few hours after you get chemo. It is usually worst during the first 4 to 6 hours after treatment and goes away within 24 hours. Delayed nausea and vomiting usually does not start until 24 hours or more after you get chemo. It can last for several days.

Which chemotherapy agent has the highest emetogenic potential?

Available pediatric experience confirms the source guideline’s ranking of cisplatin ≥ 50 mg/m2 and cyclophosphamide > 1.5 g/m2 as highly emetogenic antineoplastic agents when given as single agents.

Which chemo agent has the highest emetogenic potential?

How do you determine the emetogenicity of a chemotherapy combination?

The algorithm begins with the identification of the most emetogenic agent in the combination. The relative contribution of other chemotherapy agents to the overall emetogenicity of the combination is then assessed.

Can an emetogenic classification schema predict emetic risk following cancer chemotherapy?

An emetogenic classification schema that allows more precision in defining emetic risk, particularly in “high-risk” patient categories, could potentially facilitate new antiemetic agent development. Substantial progress has been realized over the last 15 years in predicting the risk of emesis following cancer chemotherapy.

What is the emetogenic potential of antiemetic prophylaxis?

The predicted emetogenic potential of this combination by the algorithm is level 4 (60%-90% frequency of emesis). Eighty-two percent (36/44) of patients receiving these regimens developed acute emesis when they received a placebo as antiemetic prophylaxis.

Is there an ideal emetogenic classification schema for patients receiving cisplatin?

Although the risk of delayed emesis is less than with cisplatin, up to one-third of patients receiving these agents will experience delayed emesis in the absence of delayed antiemetic prophylaxis [ 26 ]. At present, no comprehensive emetogenic classification schema that fulfills all the criteria of the “ideal” schema has been devised.